Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...
Hims & Hers health chief commercial officer sells $536,424 in stock
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a significant transaction involving ...
The Lancet9m
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...